New drug ENERGI-F705 takes first step: safety check in 24 volunteers
Knowledge-focused
Completed
This early-phase trial tested the safety and tolerability of a single dose of ENERGI-F705 tablets in 24 healthy adults aged 18 to 44. Participants were randomly assigned to receive either a 60 mg or 120 mg dose of the drug or a placebo (vehicle control). The study measured side e…
Phase: PHASE1 • Sponsor: Energenesis Biomedical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:58 UTC